Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 4/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782902 | 0.86 | KCNH2 (0.39) | KCNH2MCHR1MCHR2ACKR3GAA | |
| SCHEMBL3788446 | 0.84 | GLS (0.42) | KCNH2MCHR1MCHR2ACKR3 | |
| SCHEMBL3788883 | 0.81 | CCR2 (0.43) | KCNH2MCHR1MCHR2GAASMN1; SMN2 | |
| SCHEMBL13063421 | 0.81 | CCR2 (0.43) | KCNH2MCHR1MCHR2GAASMN1; SMN2 | |
| SCHEMBL3040635 | 0.78 | EBP (0.39) | KCNH2ACACBTACR1 | |
| SCHEMBL3791337 | 0.78 | KCNH2 (0.39) | KCNH2MCHR1MCHR2ACKR3GAA | |
| SCHEMBL3787848 | 0.78 | CCR2 (0.45) | KCNH2MCHR1MCHR2 | |
| SCHEMBL3787224 | 0.77 | CCR2 (0.39) | KCNH2MCHR1MCHR2SMN1; SMN2TACR1 | |
| SCHEMBL3742106 | 0.76 | CCR2 (0.42) | KCNH2SIGMAR1 | |
| SCHEMBL3735950 | 0.76 | CCR2 (0.42) | KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | claimed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | KCNH2 4417/4885MCHR1 325/4885MCHR2 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.